SLP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

18.06M

-4.56%

0.085

+750%

21.63M

-3.59%

0.190

+26.67%

21.34M

+4.81%

0.188

-105.6%

Estimates Revision

The market is revising Upward the revenue expectations for Simulations Plus, Inc. (SLP) for FY2026, with the revenue forecasts being adjusted by 0.17% over the past three months. During the same period, the stock price has changed by 15.79%.

Revenue Estimates for FY2026

Revise Upward

+0.17%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-5.32%

In Past 3 Month

Stock Price

Go Up

+15.79%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast SLP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

Current: 0.000

Low

16.00

Averages

16.00

High

16.00

TD Cowen

Hold

maintain

$16 -> $19

2026-01-08

New

Reason

TD Cowen

Price Target

$16 -> $19

2026-01-08

New

maintain

Hold

Reason

TD Cowen raised the firm's price target on Simulations Plus to $19 from $16 and keeps a Hold rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."

BTIG

Buy -> Neutral

downgrade

2025-12-18

Reason

BTIG

Price Target

2025-12-18

downgrade

Buy -> Neutral

Reason

BTIG downgraded Simulations Plus to Neutral from Buy without a price target. Despite early signs of stabilization in parts of the bio-pharma services market, Simulations Plus continues to face pressure, with declining recent revenues, a muted FY26 growth outlook, and a disappointing $77M write-down tied in part to a recent acquisition, the analyst tells investors in a research note Ongoing demand softness, limited visibility on a recovery, and multiple 2026 headwinds temper the firm's confidence in a near-term turnaround.

TD Cowen

Hold

initiated

$16

2025-09-30

Reason

TD Cowen

Price Target

$16

2025-09-30

initiated

Hold

Reason

TD Cowen initiated coverage of Simulations Plus with a Hold rating and $16 price target. The firm says the company's software and services biosimulation platform drives significant cost and time savings for its biopharma customers. TD is \"constructive\" on the outlook for Simulations' software revenue growth, but says a customer spending slowdown in the company's consulting services \"looms large\" while synergies from its restructuring initiatives will take time.

KeyBanc

Overweight -> Sector Weight

downgrade

2025-07-15

Reason

KeyBanc

Price Target

2025-07-15

downgrade

Overweight -> Sector Weight

Reason

KeyBanc last night downgraded Simulations Plus to Sector Weight from Overweight without a price target. The company's fiscal Q3 results and forward outlook highlighted the ongoing challenged biopharma end market environment, the analyst tells investors in a research note. The firm believes the challenges will impact Simulations Plus "more sharply" given its customer concentration and biotech exposure. KeyBanc sees weaker customer demand continuing in the near-to-middle-term with no recovery in the biotech end market.

Stephens

Overweight

downgrade

$28 -> $20

2025-07-15

Reason

Stephens

Price Target

$28 -> $20

2025-07-15

downgrade

Overweight

Reason

Stephens lowered the firm's price target on Simulations Plus to $20 from $28 and keeps an Overweight rating on the shares. Simulations Plus reported slightly better than expected quarterly results, though adjusted EBITDA guidance was slightly lower than the firm modeled, the analyst says. The fourth quarter outlook represents conservatism rather than a further slide in fundamentals, and Stephens sees limited downside from here.

Craig-Hallum

Buy

downgrade

$36 -> $31

2025-07-15

Reason

Craig-Hallum

Price Target

$36 -> $31

2025-07-15

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Simulations Plus to $31 from $36 and keeps a Buy rating on the shares. The firm notes the company reported final Q3 results with revenues slightly ahead of the pre-release range and revenue guidance for FY25 reaffirmed. Craig-Hallum believes that the headwinds the company is facing will be relatively short-term in nature and given the recent regulatory guidance which calls for more use of AI/simulation in the discovery and development of pharmaceuticals, the firm thinks Simulations Plus will return to double-digit revenue growth and adjusted EBITDA margins of 30%-plus.

Valuation Metrics

The current forward P/E ratio for Simulations Plus Inc (SLP.O) is 35.10, compared to its 5-year average forward P/E of 70.05. For a more detailed relative valuation and DCF analysis to assess Simulations Plus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

70.05

Current PE

35.10

Overvalued PE

92.02

Undervalued PE

48.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

33.17

Current EV/EBITDA

14.44

Overvalued EV/EBITDA

47.82

Undervalued EV/EBITDA

18.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

12.92

Current PS

4.54

Overvalued PS

18.98

Undervalued PS

6.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2417.79% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 2417.79% over the last month.

Sold

Bought

SLP News & Events

Events Timeline

No data

News

9.5

05:04 AMYahoo Finance

Simulations Plus Reports 3% Revenue Decline to $18.4 Million in Q1

9.5

01:03 AMNASDAQ.COM

Simulations Plus (SLP) Q1 Earnings Rise but Miss Estimates

6.0

2025-12-18Benzinga

PayPal Analyst Adopts Bearish Stance; Check Out Thursday's Top 5 Downgrades

People Also Watch

Frequently Asked Questions

What is Simulations Plus Inc (SLP) stock price today?

The current price of SLP is 18.19 USD — it has increased 0.78 % in the last trading day.

What is Simulations Plus Inc (SLP)'s business?

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

What is the price predicton of SLP Stock?

What is Simulations Plus Inc (SLP)'s revenue for the last quarter?

Simulations Plus Inc revenue for the last quarter amounts to 18.42M USD, decreased -2.66 % YoY.

What is Simulations Plus Inc (SLP)'s earnings per share (EPS) for the last quarter?

Simulations Plus Inc. EPS for the last quarter amounts to 0.03 USD, increased 200.00 % YoY.

What changes have occurred in the market's expectations for Simulations Plus Inc (SLP)'s fundamentals?

How many employees does Simulations Plus Inc (SLP). have?

Simulations Plus Inc (SLP) has 212 emplpoyees as of January 09 2026.

What is Simulations Plus Inc (SLP) market cap?

Today SLP has the market capitalization of 363.65M USD.